Kiora Pharmaceuticals, Inc. (KPRX) Stock Forecast
KPRX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $12.00 average of analyst targets
- Upside to target
- +400.0% from the latest close
- Next earnings
- November 6, 2026
- 52-week range
- $1.80 – $2.86
KPRX analyst ratings
1 analystsNumber of analysts at each rating.
KPRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KPRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.38 | −$0.38 | $0.01 | −3,900.0% | 1 |
| Current fiscal year (2026) | −$1.67 | −$1.67 | −$1.67 | −$2.60 | +35.8% | 1 |
| Next fiscal year (2027) | −$1.41 | −$1.41 | −$1.41 | −$1.67 | +15.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KPRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
KPRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KPRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.69 | −$0.69 | −$0.69 | −$0.69 | −$0.38 | −44.9% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.66 | −$2.66 | −$2.66 | −$2.66 | −$1.67 | −37.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.97 | −$1.97 | −$1.97 | −$1.97 | −$1.41 | −28.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KPRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KPRX beat in 8 of 12.
What analysts expect from KPRX
1 analysts cover Kiora Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.00, 400.0% above the latest close of $2.40. Analysts expect earnings of −$1.67 per share for 2026, +35.8% from a year earlier. For 2027 the average estimate is −$1.41 per share. Kiora Pharmaceuticals beat the EPS estimate in 8 of the last 12 quarters.
Related: KPRX income statement, KPRX key metrics, KPRX chart. See the KPRX stock overview for the latest quote and news.
KPRX forecast FAQ
What is Kiora Pharmaceuticals's price target?
The average analyst price target for Kiora Pharmaceuticals is $12.00, 400.0% above the latest close of $2.40.
Is Kiora Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Kiora Pharmaceuticals, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kiora Pharmaceuticals's EPS forecast?
Analysts forecast −$1.67 per share for 2026 (range −$1.67 to −$1.67); for 2027 the estimate is −$1.41.
When does Kiora Pharmaceuticals report earnings?
Kiora Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
Does Kiora Pharmaceuticals usually beat earnings estimates?
Kiora Pharmaceuticals reported EPS at or above the analyst estimate in 8 of the last 12 quarters.